Revision 7

Store at

#5452

Human $_{His6}$Fas Ligand/TNFSF6 (h_{His6}FasL)

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

MW (kDa):	UniProt ID:	Entrez-Gene Id:
31-36	#P48023	356

Background

FasL is a member of the TNF-superfamily family of proteins and is expressed primarily on the cell surface of activated T and NK cells (1). FasL regulates the immune response through its ability to induce apoptosis. The immunoregulatory role of FasL is underscored by lymphoadenopathy associated with FasL or Fas knockout mice and the fraction of autoimmune lympho-proliferative syndrome (ALPS) patients that have mutations in the FasL receptor, Fas (1). FasL is a membrane protein that can be cleaved into a soluble trimeric form by metalloproteinases (1,2). The soluble form of FasL retains the ability to bind to Fas, however, its ability to induce apoptosis is diminished (2). The ligation of Fas by FasL leads to the assembly of death-inducing signaling complex (DISC) and the recruitment and activation of caspase-8/caspase-10 (1,3). Active caspase-8/caspase-10 subsequently activates the "effector" caspases caspase-3 and caspase-7, and cleavage of BID (1,3).

Endotoxin

Less than 0.01 ng endotoxin/1 µg h_{His6}FasL.

Purity

>98% as determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant h_{His6}FasL. All lots are greater than 98% pure.

Source / Purification

Recombinant human$_{His6}$ FasL (h_{His6}FasL) Pro134-Leu281 (Accession #NP_000630) was expressed in human 293 cells at Cell Signaling Technology.

Bioactivity

The bioactivity of h_{His6}FasL was determined in a Jurkat cell viability assay. The ED_{50} of each lot is between 1-5 ng/ml.

Background References

1. Strasser, A. et al. (2009) *Immunity* 30, 180-92.
2. Schneider, P. et al. (1998) *J Exp Med* 187, 1205-13.
3. Guicciardi, M.E. and Gores, G.J. (2009) *FASEB J* 23, 1625-37.

Trademarks and Patents

Limited Uses

respect to any third party products or services used by Customer in connection with the Products.